

September 1, 2022

CEO buys shares in Stayble Therapeutics

Stayble Therapeutics AB ("Stayble" or the "Company") announces today that the Company's CEO Andreas Gerward has purchased 15,000 shares in the Company for a total value of 73 350 SEK. The shares have been purchased in the open market.

Andreas Gerward purchased shares on 31 August 2022 and acquired a total of 15,000 shares at a price of 4.89 SEK per share. After the transaction, Andreas owns 360 000 stocks in the Company.

For more information

Andreas Gerward, CEO Stayble Therapeutics AB

Mail: andreas.gerward@stayble.se

Phone: +46 730 808 397

About Stayble Therapeutics AB

Stayble is a clinical stage pharmaceutical company developing the injection treatment STA363 for disc-related low back pain. The treatment is aimed at patients whose back pain persists after physiotherapy and painkillers. The injection is given once and the effect is expected to remain throughout the entirety of the patient's life and to require minimal rehabilitation. The Company's focus is set upon the continued clinical development and is currently conducting a clinical phase 2b. Stayble's vision is to develop STA363 as a new standard treatment for patients suffering from chronic disc-related low back pain.

Svensk Kapitalmarknadsgranskning AB is the Company's Certified Adviser and can be reached at +46 (0) 11 32 30 732 or e-mail ca@skmq.se